Drug Profile
Research programme: autoimmune disease therapeutics - Janssen Cilag/Johnson & Johnson Innovation/Monash University
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Monash University
- Developer Janssen-Cilag; Johnson & Johnson Innovation; Monash University
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Coeliac disease
- No development reported Psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for research development in Rheumatoid-arthritis in USA
- 15 Jul 2021 Early research in Coeliac disease in USA, prior to July 2021
- 28 Feb 2019 No recent reports of development identified for research development in Psoriasis in USA